Related Experiment Video
Updated: Jul 7, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Anticoagulation in atrial fibrillation]
Christian Binggeli1, Corinna B Brunckhorst
1HerzKreislaufZentrum, Klinik für Kardiologie, Departement für Innere Medizin, Universitätsspital Zürich, Rämistrasse 100, 8091 Zürich, Schweiz. christian.binggeli@usz.ch
Insights
Atrial fibrillation increases stroke risk in the elderly. Anticoagulation effectively reduces this risk, but requires careful balancing of bleeding risks and lifestyle factors.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Context:
- Atrial fibrillation is the most prevalent cardiac arrhythmia in older adults.
- It significantly contributes to morbidity and mortality, primarily through thromboembolic events like stroke.
- Effective stroke prevention is crucial for managing patients with atrial fibrillation.
Purpose:
- To review the efficacy and risks of anticoagulation strategies for stroke prevention in atrial fibrillation.
- To compare the effectiveness of acetylsalicylic acid versus vitamin K antagonists.
- To highlight the importance of individualized risk assessment for thromboembolism and bleeding.
Summary:
- Anticoagulation therapy substantially lowers the risk of stroke and death in patients with atrial fibrillation.
- Vitamin K antagonists demonstrate superior efficacy compared to acetylsalicylic acid in reducing thromboembolic events.
- The decision to anticoagulate must weigh the benefits of stroke reduction against the increased risk of bleeding and treatment-related burdens.
Impact:
- Informs clinical decision-making regarding stroke prophylaxis in elderly patients with atrial fibrillation.
- Emphasizes the need for personalized risk-benefit assessments in anticoagulation therapy.
- Highlights the trade-offs between anticoagulation efficacy, bleeding risk, and patient lifestyle considerations.
Abstract:
Atrial fibrillation is the most common arrhythmia in the elderly and is associated with substantial morbidity and mortality, mostly due to the consequences of thromboembolism. Anticoagulation reduces the risk of stroke and death considerably, the risk reduction depending on the patient's absolute risk. Although there is modest benefit from acetylsalicylic acid, randomized trials have shown that it is consistently and substantially less effective than vitamin K antagonists. These benefits must be balanced against an increased risk of bleeding. In addition, warfarin therapy imposes a variety of lifestyle constraints, including frequent blood test monitoring and, possibly, dietary modification, and is associated with a number of drug interactions. Careful assessment of the absolute risk of stroke on the one hand and bleeding complications on the other hand will guide the use of appropriate prophylaxis against thromboembolism and its consequences.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

